Abstract:Background: Activation of the RON receptor tyrosine kinase, a member of the c-MET family, regulates tumorigenic phenotypes. The RON extracellular domains are critical in regulating these activities. The objective of this study was to determine the role of the first IPT domain in regulating RON-mediated tumorigenic activities and the underlying mechanisms.Results: Two RON variants, RON160 and RONE5/6in with deletion and insertion in the first IPT domain, respectively, were molecularly cloned. RON160 was a splicing variant generated by deletion of 109 amino acids encoded by exons 5 and 6. In contrast, RONE5/6in was derived from a transcript with an insertion of 20 amino acids between exons 5 and 6. Both RON160 and RONE5/6in were proteolytically matured into two-chain receptor and expressed on the cell surface. RON160 was constitutively active with tyrosine phosphorylation. However, activation of RONE5/6in required ligand stimulation. Deletion resulted in the resistance of RON160 to proteolytic digestion by cell associated trypsin-like enzymes. RON160 also resisted anti-RON antibody-induced receptor internalization. These features contributed to sustained intracellular signaling cascades. On the other hand, RONE5/6in was highly susceptible to protease digestion, which led to formation of a truncated variant known as RONp110. RONE5/6in also underwent rapid internalization upon anti-RON antibody treatment, which led to signaling attenuation. Although ligand-induced activation of RONE5/6in partially caused epithelial to mesenchymal transition (EMT), it was RON160 that showed cell-transforming activities in cell focus formation and anchorage-independent growth. RON160-mediated EMT is also associated with increased motile/invasive activity.Conclusions: Alterations in the first IPT domain in extracellular region differentially regulate RON mediated tumorigenic activities. Deletion of the first IPT results in formation of oncogenic variant RON160. Enhanced degradation and internalization with attenuated signaling cascades could be the mechanisms underlying non-tumorigenic features of RONE5/6in.

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Significance of the Entire C-terminus in Biological Activities Mediated by the RON Receptor Tyrosine Kinase and Its Oncogenic Variant RON160

Oncogenesis of RON Receptor Tyrosine Kinase： a Molecular Target for Malignant Epithelial Cancers

Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines.

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Blocking Tumorigenic Activities of Colorectal Cancer Cells by a Splicing RON Receptor Variant Defective in the Tyrosine Kinase Domain

Effects of Heterogously- Expressed RON Receptor Tyrosine Kinase on Motile/invasive Ability of Human Colorectal Cancer Cell Line RKO

Deletion or Insertion in the First Immunoglobulin-Plexin-Transcription (ipt) Domain Differentially Regulates Expression and Tumorigenic Activities of Ron Receptor Tyrosine Kinase

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

Alterations in a Defined Extracellular Region of the RON Receptor Tyrosine Kinase Promote RON-mediated Motile and Invasive Phenotypes in Epithelial Cells.

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

RON and RONΔ160 Promote Gastric Cancer Cell Proliferation, Migration, and Adaption to Hypoxia Via Interaction with Β-Catenin

Agonistic Monoclonal Antibodies Potentiate Tumorigenic and Invasive Activities of Splicing Variant of the RON Receptor Tyrosine Kinase

Oncogenic Variant RON160 Expression in Breast Cancer and Its Potential As a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor.

Mechanisms of RON-mediated Epithelial-Mesenchymal Transition in MDCK Cells Through the MAPK Pathway

Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways

Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.

Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.

SRSF1 and SRSF9 RNA Binding Proteins Promote Wnt Signalling‐mediated Tumorigenesis by Enhancing Β‐catenin Biosynthesis

Receptor tyrosine kinase RON and tumor